Chulhee Choi, Co-CEO of ILIAS, interviewed Hankyung

“ILIAS Biologics Inc. plans to begin a clinical trial for new exosome-based therapeutics in Australia around September.” Chulhee Choi, Co-CEO of ILIAS, said in an interview with Hankyung. ILIAS submitted a phase 1 clinical trial plan (IND) of the lead pipeline, ‘ILB-202’, to the Australian Food and Drug Administration (TGA) in February. The first clinical trial as exosome-based therapeutics in Korea is expected. Please find the link below for the full article. Interview Link(Kor.)

The release as fetched from its publisher. iliasbio.com ↗